Biohaven Ltd. (BHVN) News
Follow Biohaven Ltd. (BHVN) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 17 public stories across 9 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Biohaven Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Biohaven (BHVN)
Biohaven Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Biohaven (BHVN)
NEWS | Sep 11, 2026, 10:28 PM UTC
L
Biohaven price target maintained at $10.00 per share by HC Wainwright
HC Wainwright & Co. maintained its price target for Biohaven at $10.00 per share, according to Benzinga TradingView News ratings actions.
EQUITY | Sep 10, 2026, 05:48 PM UTC
M
Biohaven shares fall premarket after partial FDA hold on BHV-7000
Biohaven said the Food and Drug Administration placed a partial hold on the clinical program for its BHV-7000 epilepsy drug candidate. The stock was down nearly 17% to $12.50 in premarket trading.
REGULATION | Sep 10, 2026, 11:55 AM UTC
M
US FDA imposes partial clinical hold on Biohaven epilepsy trials
Biohaven said the U.S. FDA imposed a partial clinical hold, pausing new patient enrollment in its experimental epilepsy drug trials after rodent findings. The company’s shares fell more than 13% in premarket trading.
REGULATION | Sep 10, 2026, 11:34 AM UTC
M
Biohaven pauses new U.S. enrollment after FDA partial clinical hold
Biohaven paused new U.S. patient enrollment in its BHV-7000 program after an FDA partial clinical hold. Dosing continues for already randomized patients.
EQUITY | Sep 10, 2026, 10:13 AM UTC
L
Biohaven cut to sector perform; RBC Capital lowers target
RBC Capital downgraded Biohaven to sector perform from outperform and cut its price target to $19.00/share from $23.00, per TradingView News citing Benzinga.
EQUITY | Sep 08, 2026, 02:39 PM UTC
L
BHVN rises on SK Biopharmaceuticals epilepsy drug license
BHVN is trading higher following SK Biopharmaceuticals’ license for an epilepsy drug, with retail now awaiting an obesity trial readout.
EQUITY | Aug 26, 2026, 05:00 PM UTC
L
Biohaven shares rise on epilepsy drug licensing deal
Biohaven shares gained following a licensing deal tied to an epilepsy drug, according to TradingView News.
EQUITY | Aug 26, 2026, 03:57 PM UTC
L
JOYY rises in premarket after quarterly results
JOYY shares rose 3.6% in premarket trading after the company reported second-quarter earnings of $1.24 per share versus $1.28 expected and sales of $590.754 million versus $574.118 million expected.
EARNINGS | Aug 26, 2026, 09:22 AM UTC
M
Biohaven signs $795 million epilepsy drug licensing deal
Biohaven signed an epilepsy drug licensing deal with SK Biopharm valued at $795 million, per TradingView News.
EQUITY | Aug 26, 2026, 07:59 AM UTC
L
Biohaven and SK Biopharmaceuticals sign global licensing deal
Biohaven and SK Biopharmaceuticals entered into a strategic global licensing agreement for a Kv7 ion channel platform and opakalim for epilepsy.
EQUITY | Aug 26, 2026, 06:53 AM UTC
M
Federal court judgment formalizes $4 million trade-secret award
Federal court entered judgment confirming RA Capital and Avilar Therapeutics misappropriated a Yale-developed trade secret and formalized a $4 million award to Biohaven and Yale University.
EQUITY | Aug 25, 2026, 08:42 PM UTC
L
Biohaven Appoints John Yetimoglu To Board
Biohaven appoints new board member
EQUITY | Aug 06, 2026, 11:01 AM UTC
H
BHVN Biohaven to present new clinical data at esmo Congress on bhv-1530, a novel fgfr3-directed Adc with a proprietary topoisomerase I (topo
BHVN Biohaven to present new clinical data at esmo Congress on bhv-1530, a novel fgfr3-directed Adc with a proprietary topoisomerase I (topoix) payload
GEOPOLITICS | Jul 20, 2026, 11:30 AM UTC
H
ManpowerGroup Posts Upbeat Q2 Earnings, Joins Docebo, Zentalis Pharmaceuticals And Other Big Stocks Moving Higher On Friday
U.S. stocks were lower, with the Nasdaq Composite falling around 400 points on Friday. Shares of ManpowerGroup Inc (NYSE: MAN ) rose sharply after the company reported upbeat second-quarter results and issued third-quart
EARNINGS | Jul 17, 2026, 02:09 PM UTC
M
Analyst Warns Biohaven's Lead Drug May Struggle To Stand Out
Biohaven Ltd. (NYSE: BHVN ) shares fell Monday after Bank of America Securities (BofA) downgraded the biotechnology company, citing an unfavorable risk-reward profile ahead of a key late-stage epilepsy trial. BofA analys
EQUITY | Jun 29, 2026, 06:04 PM UTC
M
B of A Securities Downgrades Biohaven to Underperform, Lowers Price Target to $11
Bank of America Securities downgrades Biohaven to Underperform.
EQUITY | Jun 29, 2026, 11:44 AM UTC